Drug
Cemdisiran clinical trials
- studies test it
- 14
- open now
- 4
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the cemdisiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- ALN-CC5
- 11
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
Regeneron Pharmaceuticals (9) · Alnylam Pharmaceuticals (3) · Austin Neuromuscular Center (1) · Mario Negri Institute for Pharmacological Research (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses cemdisiran is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyRecruitingPhase 3Regeneron PharmaceuticalsNCT06541704Written as Cemdisiran
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksRecruitingPhase 3Regeneron PharmaceuticalsNCT05744921Written as Cemdisiran
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyRecruitingPhase 3Regeneron PharmaceuticalsNCT07154745Written as Cemdisiran
- Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisRecruitingEarly Phase 1Austin Neuromuscular CenterNCT06479863Written as Pozelimab/Cemdisiran
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT05070858Written as Pozelimab + Cemdisiran
- Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab TherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04888507Written as Cemdisiran
- Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyCompletedPhase 2Regeneron PharmaceuticalsNCT04811716Written as Cemdisiran
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaTerminatedPhase 3Regeneron PharmaceuticalsNCT05131204Written as Cemdisiran
- A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)TerminatedPhase 2Alnylam PharmaceuticalsNCT03841448Written as Cemdisiran
- A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04940364Written as Cemdisiran
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult VolunteersCompletedPhase 1Regeneron PharmaceuticalsNCT04601844Written as Cemdisiran
- Eculizumab to Cemdisiran Switch in aHUSWithdrawnPhase 2Mario Negri Institute for Pharmacological ResearchNCT03999840Written as cemdisiran
- A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNHCompletedPhase 1/2Alnylam PharmaceuticalsNCT02352493Written as ALN-CC5
- A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnPhase 2Alnylam PharmaceuticalsNCT03303313Written as Cemdisiran
Given in every arm · 1 — cemdisiran is usual care beside what is tested
Codes
What other systems call cemdisiran · ClinicalTrials.gg INT017860
- UNII (FDA) S66Z65E10TCEMDISIRANOne source FDA
- NCI Thesaurus C120319CemdisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S66Z65E10T | CEMDISIRAN | One source FDA |
| NCI Thesaurus | C120319 | Cemdisiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.